June 27, 2016 — Janssen Pharmaceuticals is accused of downplaying the risk of gynecomastia in the fifth Risperdal lawsuit to go to trial in Philadelphia.
The plaintiff is Andrew Yount, a man who was born in 1998. He started taking Risperdal in 2003 to treat attention-deficit hyperactivity disorder and oppositional defiant disorder. He began growing breasts in 2004.
Risperdal was only approved for adults with schizophrenia until 2006, when it gained approval for children with autism-induced irritability.
The label reassured patients that gynecomastia was a “rare” side effect that occurred in fewer than one in 1,000 patients. However, a recent investigative report by Steven Brill highlighted the “creative math” Janssen Pharmaceuticals used to downplay gynecomastia.
Janssen made it seem like only 0.8% of boys developed gynecomastia, when in reality the number was closer to 4.5%. the drug-make is accused of failing to warn about gynecomastia to protect profits.
Yount’s mother filed the lawsuit in 2013 after seeing a lawyer’s ad on TV. His doctors tried to switch him to another medication but Yount continues taking generic Risperdal, according to The Legal Intelligencer.
The lawyer representing Yount successfully convinced another jury in Philadelphia to award $1.75 million to a boy from Maryland last year. One month later, another jury awarded $500,000 to a boy with gynecomastia.
Do I have a Risperdal Lawsuit?
The Schmidt Firm, PLLC is currently accepting Risperdal induced injury cases in all 50 states. If your son was diagnosed with gynecomastia, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.